0001415889-24-009073.txt : 20240325 0001415889-24-009073.hdr.sgml : 20240325 20240325204009 ACCESSION NUMBER: 0001415889-24-009073 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240321 FILED AS OF DATE: 20240325 DATE AS OF CHANGE: 20240325 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scheiner Zachary CENTRAL INDEX KEY: 0001816523 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40532 FILM NUMBER: 24780700 MAIL ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 18TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LENZ Therapeutics, Inc. CENTRAL INDEX KEY: 0001815776 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 844867570 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 445 MARINE VIEW AVE SUITE 320 CITY: DEL MAR STATE: CA ZIP: 92014 BUSINESS PHONE: 858-925-7000 MAIL ADDRESS: STREET 1: 445 MARINE VIEW AVE SUITE 320 CITY: DEL MAR STATE: CA ZIP: 92014 FORMER COMPANY: FORMER CONFORMED NAME: Graphite Bio, Inc. DATE OF NAME CHANGE: 20210312 FORMER COMPANY: FORMER CONFORMED NAME: Integral Medicines, Inc. DATE OF NAME CHANGE: 20200622 4 1 form4-03262024_120359.xml X0508 4 2024-03-21 0001815776 LENZ Therapeutics, Inc. LENZ 0001816523 Scheiner Zachary C/O RA CAPITAL MANAGEMENT 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116 true false false false 0 Stock Option (right to buy) 15.05 2024-03-21 4 A 0 27000 0 A 2034-03-20 Common Stock 27000 27000 D Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus II Fund") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund, the Nexus II Fund and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. /s/ Zachary Scheiner 2024-03-25